Vonoprazan-based triple therapy for Helicobacter pylori resistant to first-line regimens: A guideline-compliant 14-day multicenter study in Egypt
Fourteen-day vonoprazan-amoxicillin-metronidazole achieved high eradication rates in dual-resistant H. pylori with substantial symptom and laboratory improvements and an acceptable safety profile. This regimen represents a viable salvage option where first-line therapies fail.
Authors
- Atteyat A. Semeya
- Rania Hafez (ORCID: https://orcid.org/0000-0003-0596-0249)
- Rasha Elgamal (ORCID: https://orcid.org/0009-0000-5327-7052)
- Amira A. A. Othman (ORCID: https://orcid.org/0000-0002-8191-0035)
- Naglaa F. Al-Mihy
Institutions
- Suez University (EG)
- Damanhour University (EG)
- Benha University (EG)
Publication Details
- Journal
- Journal of Infection and Public Health
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1016/j.jiph.2025.103015
- Citations
- 1
- Primary Topic
- Helicobacter pylori-related gastroenterology studies
- Type
- article
- Field-Weighted Citation Impact
- 2.01